✦ LIBER ✦

High-dose 5-fluorouracil plus low dose methotrexate plus or minus low-dose PALA in advanced colorectal cancer: a randomised phase II-III trial of the EORTC Gastrointestinal Group

✍ Scribed by J Wils; G.H Blijham; Th Wagener; J De Greve; R.L.H Jansen; T.C Kok; J.W.R Nortier; H Bleiberg; M.L Couvreur; B Genicot; B Baron

Book ID: 117659199
Publisher: Elsevier Science
Year: 2003
Tongue: English
Weight: 153 KB
Volume: 39
Category: Article
ISSN: 0959-8049
DOI: 10.1016/s0959-8049(02)00662-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase II trial of weekly high dose con

A phase II trial of weekly high dose continuous infusion 5-fluorouracil plus oral leucovorin in patients with advanced colorectal cancer

✍ Enrique Aranda; Andrés Cervantes; Javier Dorta; Esperanza Blanco; Carlos Fernánd 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 419 KB 👁 2 views

Background. In a previous Phase I1 trial, the authors showed that a weekly continuous infusion of 5-fluorouracil (5-FU) at a dose of 3.5 g/mz for 48 hours is an active treatment for advanced colorectal cancer. The overall response rate was 38.5%, and the median survival was 12 months. These data wer

Phase III trial of bolus 5-fluorouracil

Phase III trial of bolus 5-fluorouracil (5-FU)/folinic acid (FA) (MAYO) vs. weekly oxaliplatin (OXA) plus high dose 24h 5-FU infusion/FA in patients with advanced colorectal cancer (CRC)

✍ A. Grothey; T. Buechele; H. Kroening; K. Ridwelski; P. Reichardt; A. Kretzschmar 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 163 KB

732 Modulation of weekly high dose infus

732 Modulation of weekly high dose infusional 5-fluorouracil (FU) by leucovorin (LV), α-interferon (IFN) or LV plus IFN in advanced colorectal cancer. Results of a multicenter randomized trial of the AIO

✍ C.H. Köhne; P. Schöffski; H. Wilke; C. Käufer; H. Rauschecker; R. Andreesen; U. 📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 153 KB